A bill which would allow terminally ill Nebraskans to try experimental drugs advances in the Unicameral.

Senator Robert Hilkemann of Omaha sponsors the measure.

Medication would have had to pass phase one of FDA trials and must be recommended by a physician and used with informed consent.

In addition, the terminally ill patient would have had to exhaust all other conventional means of treatment.

The bill cleared the first hurdle on a 33-to-12 vote despite warnings such as the one issued by Senator John Kuehn of Heartwell, who points out the bill frees pharmaceutical companies of liability if the experiment backfires.

Others question the constitutionality of the bill. Still, it moved to the second round of debate.